A new generation of treatments for Hepatitis C are becoming available. Theses treatments offer the prospect higher success rates, being on treatment for less time, and fewer side affects (particularly those associated with interferon).
Haemophilia Scotland believes that patients, in consultation with healthcare professionals, should have access to the new treatments to give as much choice as possible. We have, therefore, made representations and submissions to the Scottish Medicines Consortium (SMC) who decide which newly licensed drugs represent good value for money to NHS Scotland in favour of the new treatments.
The Irish Haemophilia Society have kindly given us permission republish their extremely informative newsletter, Posititve News, which gives much more detailed information about the current treatment situation for Hepatitis C.
Ombitasvir/Paritaprevir/Ritonavir (Viekirax®) and Dasabuvir (Exviera®)